Results 11 to 20 of about 1,334 (146)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials

Ophthalmology and Therapy, 2023
Introduction This review aims to assess the efficacy, durability and safety of faricimab—a dual vascular endothelial growth factor and angiopoietin 2 inhibitor—in patients with neovascular age-related macular degeneration (nAMD) and diabetic macula ...
Helene O. Larsen, Jakob Grauslund, Anna S. Vergmann   +2 more
doaj   +1 more source

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration

Scientific Reports, 2023
Though vascular endothelial growth factors (VEGF) and other proangiogenic factors, such as angiopoietins (Ang), may be involved in the development of neovascular age-related macular degeneration (nvAMD), only drugs that inhibit the VEGF family are ...
Ryosuke Tamiya, Masayuki Hata, Asako Tanaka, Memiri Tsuchikawa, Naoko Ueda-Arakawa, Hiroshi Tamura, Manabu Miyata, Ayako Takahashi, Ai Kido, Yuki Muraoka, Masahiro Miyake, Sotaro Ooto, Akitaka Tsujikawa   +12 more
doaj   +1 more source

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties

International Journal of Retina and Vitreous, 2023
Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure and function of the biologics.
Øystein Kalsnes Jørstad, Stian Foss, Torleif Tollefsrud Gjølberg, Simone Mester, Mari Nyquist-Andersen, Magne Sand Sivertsen, Dag Fossum, Espen Gleditsch, Morten Carstens Moe, Jan Terje Andersen   +9 more
doaj   +1 more source

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept

Medicina, 2023
Background and Objectives: Faricimab is the first intravitreal injection of vascular endothelial growth factor-A and angiopoietin-2 bispecific monoclonal antibody.
Hiromi Ohara, Yosuke Harada, Tomona Hiyama, Ayako Sadahide, Akira Minamoto, Yoshiaki Kiuchi   +5 more
doaj   +1 more source

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology, 2023
Ella H Leung, Daniel J Oh, Shannon E Alderson, Joshlynn Bracy, Mia McLeod, Litzi I Perez, Alexander Bottini, David Chin Yee, Krishna Mukkamala Georgia Retina, Atlanta, GA, USACorrespondence: Ella H Leung, 833 Campbell Hill St NW, Suite 300, Marietta, GA,
Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, Bottini A, Chin Yee D, Mukkamala K   +8 more
doaj  

Faricimab for Treatment-Resistant Diabetic Macular Edema

Clinical Ophthalmology, 2022
To assess the short-term outcomes in treatment-resistant diabetic macular edema (DME) patients changed from intravitreal aflibercept (IVA) to intravitreal faricimab (IVF).A retrospective review was undertaken on DME subjects receiving IVA therapy at a single private practice. Patients were separated into study and control cohorts.
Ryan B Rush, Sloan W Rush
openaire   +3 more sources

Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis

Pharmacological Research
Background: Faricimab stands as the inaugural and sole bispecific antibody approved by the US Food and Drug Administration (FDA) for intravitreal injection. Nonetheless, the efficacy and safety of intravitreal faricimab remained uncertain.
Guanran Zhang, Xin Wen, Yanrong Li, Junran Sun, Huixun Jia, Xiaodong Sun   +5 more
doaj   +1 more source

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion

Ophthalmology Science, 2023
Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration.
Lars-Olof Hattenbach, MD, PhD, Francis Abreu, PhD, Pablo Arrisi, PhD, Karen Basu, PhD, Carl J. Danzig, MD, Robyn Guymer, MD, PhD, Zdenka Haskova, MD, PhD, Jeffrey S. Heier, MD, Aachal Kotecha, PhD, Ying Liu, PhD, Anat Loewenstein, MD, András Seres, MD, Jeffrey R. Willis, MD, PhD, Charles C. Wykoff, MD, PhD, Liliana P. Paris, MD, PhD   +14 more
doaj   +1 more source

Evaluating the Real-World Efficacy and Safety of Intravitreal Faricimab in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review

IJRETINA (International Journal of Retina)
Introduction: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in the elderly. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized the treatment of nAMD ...
Dany Petra Pranata Barus, Gitalisa Andayani Adriono   +1 more
doaj   +1 more source

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes   +8 more
wiley   +1 more source